Developing biologics that target ROCK or upregulate MLCK may be of profound value in conditions where aberrant and increased invasion is seen in keratinocytes, such as in pathological conditions like keratinocyte cancers and inflammation. Here, MYLK is linked to keratinocyte carcinoma.